• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cyanotech Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events

    8/22/25 6:01:46 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CYAN alert in real time by email
    cyan20250821_8k.htm
    false 0000768408 0000768408 2025-08-21 2025-08-21


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 8-K
     
    Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    August 21, 2025
    Date of Report: (Date of earliest event reported)
     
    Cyanotech Corporation
    (Exact name of registrant as specified in its charter)
     
    Nevada
    (State or other jurisdiction of
    incorporation)
    000-14602
    (Commission File Number)
    91-1206026
    (IRS Employer Identification
    Number)
     
     
    73-4460 Queen Kaahumanu Highway, Suite #102, Kailua Kona, HI 96740
    (Address of principal executive offices)
     
    (808) 326-1353
    (Registrant’s telephone number)
     
    Not Applicable
    (Former name or former address, if changed since last report)
     
    Securities registered pursuant to Section 12(b) of the Act: None
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     

     
     
    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
     
    On August 21, 2025, Cyanotech Corporation, a Nevada corporation (the “Company”), named Jennifer Miyashiro, age 45, as its Chief Financial Officer (“CFO”), Vice President (“VP”) of Finance and Administration, and Treasurer. In connection with the foregoing appointment, Jennifer Rogerson resigned from her position with the Company.
     
    In connection with Ms. Miyashiro’s appointment, she will receive an annual base salary of $195,000 and will be eligible to receive a fiscal year-end bonus per the Management Bonus Plan, subject to the Company’s pretax profit and distributed as part of an overall management bonus program. After her appointment, Ms. Miyashiro will receive options to purchase 50,000 shares of the Company’s common stock (the “Options”) under the Company’s 2016 Equity Incentive Plan (the “Plan”), subject to the terms of the Plan and a Stock Option Grant Notice and Option Agreement. The exercise price per share of the Options will be the closing price on the date of grant. The Options will vest over three years at 16,666 shares for the first year and 16,667 shares per year for the remaining two years. Ms. Miyashiro will be eligible to participate in all other employee benefit plans and compensation programs that the Company maintains for salaried employees and executive officers.
     
    Ms. Miyashiro joined the Company in May 2025 as Senior Director of Financial Planning and Analysis. She is a seasoned financial professional with over twenty-five years of experience in accounting, financial planning and corporate strategy. From 2012 to 2025, Ms. Miyashiro held several leadership roles at Hawaiian Airlines, most recently serving as Senior Director of Corporate Planning and Financial Planning and Analysis, where she oversaw enterprise-wide financial planning and initiatives. From 2000 to 2012, Ms. Miyashiro spent twelve years at Xilinx, Inc., advancing through roles of increasing responsibility, developing expertise in financial management and business operations. She holds a Master of Business Administration from San Jose State University and a Bachelor of Science degree in Accounting from Santa Clara University.
     
    Item 5.07 Submission of Matters to a Vote of Security Holders.
     
    On August 21, 2025, the Company held its 2025 Annual Meeting of the Stockholders (the “Annual Meeting”). The Stockholders elected the four nominees to the Board of Directors (the “Board”) named in the proxy statement and ratified the selection of BPM LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026. The final results for the votes regarding each item or proposal are set forth below. The proposals are described in detail in the Company’s proxy statement filed with the Securities and Exchange Commission on July 10, 2025.
     
     1.    To elect four directors among the nominees named in the proxy statement.
     
    Name
    Votes For
    Votes Withheld
    Broker Non-Votes
    Matthew K. Custer
    4,080,123
    60,551
    1,186,839
    Michael A. Davis
    4,017,112
    123,562
    1,186,839
    David M. Mulder
    4,018,081
    122,593
    1,186,839
    David L. Vied
    4,024,070
    116,604
    1,186,839
     
    2.     To ratify the selection of BPM LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026.
     
    Votes For
    Votes Against
    Abstentions
    Broker Non-Votes
    5,167,992
    155,517
    4,004
    -
     
    3.     To hold an advisory vote on the frequency of future advisory votes on the compensation of our Named Executive Officers.
     
    3 YRS
    2 YRS
    1 YR
    Abstentions
    Non-Votes
    3,953,481
    20,675
    136,864
    29,654
    1,186,839
     
    Based on the results of the vote regarding the frequency of future advisory votes on the compensation of our Named Executive Officers, the Company will continue to provide an advisory vote on executive compensation every three years.
     
     

     
     
    Item 8.01 Other Events.
     
    On August 21, 2025, the Company held the Annual Organization Meeting (the “Organizational Meeting”) of the Board. During the Organizational Meeting, it was resolved that Michael A. Davis, appointed Chairman of the Board, David M. Mulder and David L. Vied were all determined to be independent directors under Section 1.1(9) of the OTCQB Listing Rules. Also resolved was the appointment of committee members to the Board concurrent with their terms as directors, or until their earlier resignation or removal from such committee.
     
    Audit Committee
    Nominating and Corporate
    Governance Committee
    Compensation Committee
    David M. Mulder (Chair)
    Michael A. Davis (Chair)
    David L. Vied (Chair)
    David L. Vied
    David L. Vied
    Michael A. Davis
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    CYANOTECH CORPORATION 
     
           
           
           
    Dated: August 22, 2025 
    /s/ Matthew K. Custer
     
     
    By:
    Matthew K. Custer
     
       
    President and Chief Executive Officer
     
     
     
    Get the next $CYAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    10/3/24 3:27:06 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    10/1/24 4:42:34 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/27/24 1:33:41 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    SEC Filings

    View All

    SEC Form 10-Q filed by Cyanotech Corporation

    10-Q - CYANOTECH CORP (0000768408) (Filer)

    11/10/25 4:02:12 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - CYANOTECH CORP (0000768408) (Filer)

    9/2/25 9:30:08 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events

    8-K - CYANOTECH CORP (0000768408) (Filer)

    8/22/25 6:01:46 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/16/25 3:40:05 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Miyashiro Jennifer A.S.

    3 - CYANOTECH CORP (0000768408) (Issuer)

    9/12/25 3:24:28 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/2/25 6:19:32 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter of fiscal year 2026, ended September 30, 2025. Commenting on the second quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Our second quarter reflected continued momentum in both sales growth and profitability. Total sales increased 19.3% year-over-year, driven by higher bulk sales and strong performance in our online channels. "We also saw meaningful improvement in gross margin as our production volumes continued to increase, driving lower per

    11/10/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2026, ended June 30, 2025. Commenting on the first quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "While top-line revenue remained relatively flat compared to the prior year, I am encouraged by the meaningful improvement in both gross margin and net loss reduction. Our margin expansion, from 25.0% in the prior year to 30.5%, reflects the continuation of strong operational discipline and improved production efficiency." "We re

    8/6/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

    Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2025, ended March 31, 2025. Commenting on the fiscal year results (changes shown vs. fiscal 2024), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal 2025 was a year of meaningful progress for Cyanotech. Revenue grew 5%, gross margin improved by nearly 3 points and we reduced our operating loss by almost 45%." "Looking ahead, we remain cautious. Economic uncertainty, shifting demand and potential new tariffs could impact costs and global markets. W

    6/20/25 12:00:00 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Leadership Updates

    Live Leadership Updates

    View All

    Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

    Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

    8/1/23 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Financials

    Live finance-specific insights

    View All

    Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter of fiscal year 2026, ended September 30, 2025. Commenting on the second quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Our second quarter reflected continued momentum in both sales growth and profitability. Total sales increased 19.3% year-over-year, driven by higher bulk sales and strong performance in our online channels. "We also saw meaningful improvement in gross margin as our production volumes continued to increase, driving lower per

    11/10/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2026, ended June 30, 2025. Commenting on the first quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "While top-line revenue remained relatively flat compared to the prior year, I am encouraged by the meaningful improvement in both gross margin and net loss reduction. Our margin expansion, from 25.0% in the prior year to 30.5%, reflects the continuation of strong operational discipline and improved production efficiency." "We re

    8/6/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

    Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2025, ended March 31, 2025. Commenting on the fiscal year results (changes shown vs. fiscal 2024), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal 2025 was a year of meaningful progress for Cyanotech. Revenue grew 5%, gross margin improved by nearly 3 points and we reduced our operating loss by almost 45%." "Looking ahead, we remain cautious. Economic uncertainty, shifting demand and potential new tariffs could impact costs and global markets. W

    6/20/25 12:00:00 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    10/3/24 6:39:03 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    9/12/24 12:25:52 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    9/6/24 12:45:58 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care